Biomarin Pharmaceutical (NASDAQ:BMRN) reported its Q3 earnings results on Wednesday, October 27, 2021 at 04:05 PM.
Here’s what investors need to know about the announcement.
Earnings
Biomarin Pharmaceutical beat their estimated earnings by 20.0%, reporting an EPS of $-0.2 versus an estimate of $-0.25, which surprised analysts.
Revenue was up $68,042,000 from the same period last year.
Past Earnings Performance
Last quarter the company beat on EPS by $0.18, which was followed by a 0.28% drop in the share price the next day.
Here’s a look at Biomarin Pharmaceutical’s past performance:
| Quarter | Q2 2021 | Q1 2021 | Q4 2020 | Q3 2020 |
|---|---|---|---|---|
| EPS Estimate | -0.11 | -0.10 | -0.19 | 1.29 |
| EPS Actual | 0.07 | 0.09 | 0.12 | 4.01 |
| Revenue Estimate | 448.79M | 446.45M | 440.23M | 454.64M |
| Revenue Actual | 501.69M | 486.03M | 452.12M | 476.78M |
To track all upcoming earnings announcements, click to use Benzinga Earnings Calendar.
